WaveMan
WaveMan · Company
CGON · Cg Oncology, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

CGON CG Oncology (CGON) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001991792
Quote by TradingView
Form 144 · 20
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
129
13F, latest reported quarter
Conversions, 180 days
10
Codes C/M, not in net · $671.4K priced

What the filings say about CGON

Insiders, 180 days
+$21.9M net bought
1 buyer · 2 sellers · 27% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$45.0M
20 notices

CG Oncology insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, CG Oncology, Inc. insiders bought a net $21.9M of stock across 52 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
POST LEONARD E
Director
SELL
2026-10-19 SECtraded 2026-10-15
500
$30.8K
-0.4%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Sep 15, 2026.
  • The trade is 100.0% of the 500 shares held after it.
  • No other insider sold within 30 days.
  • 129 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director POST LEONARD E sold about $30.8K of CGON under a 10b5-1 plan on Oct 15, 2026; 129 funds added in the latest 13F quarter.
POST LEONARD E
Director
SELL
2026-10-19 SECtraded 2026-10-15
500
$31.2K
-0.4%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Sep 15, 2026.
  • No other insider sold within 30 days.
  • 129 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director POST LEONARD E sold about $31.2K of CGON under a 10b5-1 plan on Oct 15, 2026; 129 funds added in the latest 13F quarter.
POST LEONARD E
Director
SELL
2026-09-17 SECtraded 2026-09-15
1,000
$73.0K
-17.3%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Aug 14, 2026.
  • No other insider sold within 30 days.
  • 129 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director POST LEONARD E sold about $73.0K of CGON under a 10b5-1 plan on Sep 15, 2026; 129 funds added in the latest 13F quarter.
POST LEONARD E
Director
SELL
2026-08-18 SECtraded 2026-08-14
1,000
$74.5K
-23.5%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Jul 15, 2026.
  • No other insider sold within 30 days.
  • 129 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director POST LEONARD E sold about $74.5K of CGON on Aug 14, 2026; 129 funds added in the latest 13F quarter.
POST LEONARD E
Director
SELL
2026-07-17 SECtraded 2026-07-15
1,000
$71.2K
-12.1%
Context
  • 17 earlier Form 4 trades (code P or S) here by this insider (17 sales), the last on Jun 24, 2026.
  • 1 other insider sold within 30 days.
  • 129 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director POST LEONARD E sold about $71.2K of CGON on Jul 15, 2026; 1 other insider sold within 30 days and 129 funds added in the latest 13F quarter.
52 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 47 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$21.9M over 180 days
-$209.6K over 90 days
more than 97% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
129 funds bought in last quarter
more than 78% of Pharma & Biotech
Revenue
+254.7% year over year
more than 91% of Pharma & Biotech
Margin
-3985.0% net margin
below 95% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
15.3% of the float short (float per yahoo 2026-10-26) · 8.5 days to cover · settled 2026-09-30
more than 77% of Pharma & Biotech
What changed in the last 30 days
Oct 19Director POST LEONARD E sold $62.1K under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 15Director LEONARD POST filed to sell $185.5K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch CGON

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+47.2%12M
-11%+24%+58%+93%2025-102025-122026-022026-042026-062026-082026-10 2026-06-25 · Liu Brian Guan-Chyun bought $24.8M2026-07-10 · Mulay James sold $1.8M2026-04-17 · Mulay James sold $1.1M2026-01-09 · Mulay James sold $555.9K2026-06-24 · POST LEONARD E sold $350.0K2026-06-22 · POST LEONARD E sold $325.0K2026-03-16 · Mulay James sold $83.2K2026-06-15 · Mulay James sold $78.8K2026-08-14 · POST LEONARD E sold $74.5K2026-09-15 · POST LEONARD E sold $73.0K2026-07-15 · POST LEONARD E sold $71.2K2026-06-04 · POST LEONARD E sold $54.5K2026-03-16 · Mulay James sold $41.5K2025-11-17 · POST LEONARD E sold $41.4K2026-06-15 · Mulay James sold $39.3K2026-10-15 · POST LEONARD E sold $31.2K2026-10-15 · POST LEONARD E sold $30.8K2026-01-09 · Mulay James sold $28.9K2026-10-15 · LEONARD POST filed to sell $185.5K2026-09-21 · AMBAW BELLETE filed to sell $2.3M2026-09-17 · AMBAW BELLETE filed to sell $499.7K2026-09-11 · AMBAW BELLETE filed to sell $62.0K2026-09-02 · AMBAW BELLETE filed to sell $2.3M2026-08-31 · AMBAW BELLETE filed to sell $3.8M2026-08-27 · AMBAW BELLETE filed to sell $459.6K2026-08-25 · AMBAW BELLETE filed to sell $839.3K2026-08-24 · AMBAW BELLETE filed to sell $458.2K2026-08-19 · AMBAW BELLETE filed to sell $8.0M2026-08-17 · AMBAW BELLETE filed to sell $4.0M2026-08-14 · AMBAW BELLETE filed to sell $1.5M2026-08-13 · AMBAW BELLETE filed to sell $2.0M2026-08-12 · AMBAW BELLETE filed to sell $2.5M2026-08-11 · AMBAW BELLETE filed to sell $3.8M2026-08-10 · AMBAW BELLETE filed to sell $3.8M2026-08-07 · AMBAW BELLETE filed to sell $696.1K2026-08-06 · AMBAW BELLETE filed to sell $5.7M2026-08-05 · AMBAW BELLETE filed to sell $1.8M2026-07-29 · AMBAW BELLETE filed to sell $316.3K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CGON: institutional holders (13F)

13F holdings, latest reported quarter
RTW INVESTMENTS, LP
8,514,590 sh
$605.0M
Decheng Capital LLC
6,371,669 sh
$452.7M
BlackRock, Inc.
6,256,288 sh
$444.5M
WELLINGTON MANAGEMENT GROUP LLP
5,324,751 sh
$378.3M
FMR LLC
4,161,493 sh
$295.7M

Congress trades in CGON

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CGON planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
LEONARD POST
Filed 2026-10-15
$185.5K
AMBAW BELLETE
Filed 2026-09-21
$2.3M
AMBAW BELLETE
Filed 2026-09-17
$499.7K
AMBAW BELLETE
Filed 2026-09-11
$62.0K
AMBAW BELLETE
Filed 2026-09-02
$2.3M

CGON mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$5.4M position · as of 2026-05-31
3.4%
Tema Oncology ETF
$4.3M position · as of 2026-05-31
2.4%
Eventide Healthcare & Life Sciences Fund
$26.0M position · as of 2026-06-30
1.5%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$128.8M position · as of 2026-06-30
1.2%
PROFUND VP BIOTECHNOLOGY
$569.6K position · as of 2026-06-30
1.2%
Franklin Biotechnology Discovery Fund
$12.4M position · as of 2026-07-31
1.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 2
1 active
2
Phase 3
2 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$11.9M
$28.6M
$2.3M
+12%
+31%
2024
$11.2M
$23.4M
$7.5M
-23%
-2%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $21.9M bought by insiders over 180 days, 129 funds added last quarter, $45.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

CGON financials

Revenue growth
+254.7%
XBRL, annual
Net margin
-3985.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-3,603%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$179.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-59.49x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-26.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-25.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-29.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$5.5B
market value at close 2026-10-23 on 2026-08-05 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-3.3%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Revenue$4.0M$1.1M$204.0K
Operating income-$190.8M-$114.7M-$55.4M
Net income-$161.0M-$88.0M-$48.6M
EPS (diluted)-2.08-1.41-15.65
Operating cash flow-$132.3M-$78.7M-$45.7M
Cash$32.5M$257.1M$8.3M
Long-term debt$3.0M$0n/a
SEC XBRL, fiscal years, as known on 2026-10-27

CGON Stock Sonar score 6/7 axes

Find similar shapesCompare

CGON ranks highest on growth (91st percentile) and institutional and government (78th), and lowest on financial health (46th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
67
Inputs
  • Return on equity-26.4% · 69 pct, sector of 545
  • Return on assets-25.1% · 64 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-29.6% · 68 pct, sector of 576
Financial health
46
Inputs
  • Debt to equity0.00x · 82 pct, sector of 352
  • Cash flow to debt-59.49x · 9 pct, sector of 371
Growth
91
Inputs
  • Revenue growth, YoY+254.7% · 91 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
77
Inputs
  • Net Form 4 buying (codes P and S), 180d$22.0M · 97 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
78
Inputs
  • Funds adding, latest quarter129 · 78 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
50
Inputs
  • Short interest, % of float+15.3% · 25 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.6% · 75 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

CGON filings, in plain words

Are CG Oncology insiders buying or selling CGON?

In the 180 days to 2026-10-27, CG Oncology insiders were net buyers, a net $21.9M: $24.8M of purchases and $2.9M of sales reported on Form 4, by 1 buyer and 2 sellers.

Are there planned insider sales of CGON?

Yes. 20 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $45.0M of stock; the latest, by LEONARD POST, was filed 2026-10-15.

Read the full summary

In the 180 days to 2026-10-27, CG Oncology insiders were net buyers of CGON, a net $21.9M across purchases and sales reported on Form 4 by 1 buyer and 2 sellers. 27% of the 11 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 20 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $45.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies